Sunday, 25 May 2025
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Accreditation
    • Contact Us
  • Newsletters
  • Continuing Education
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • CLL in Rural America
    • Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL

Peter Johnson, MA, MD, FRCP

Professor of Medical Oncology
University of Southampton
Southampton, United Kingdom
Last modified: November 26, 2018
Authored Items
Use and Abuse of PET Imaging in Hodgkin Lymphoma
Peter Johnson, MA, MD, FRCP
Clinical Expert Commentaries published on December 11, 2014
The Role of Clinical Prognostic Factors in the PET Era
Peter Johnson, MA, MD, FRCP
EHA 2014: Meeting Highlights in Hodgkin Lymphoma published on July 16, 2014
Responses and Chemotherapy Dose Adjustment Determined by PET-CT: RATHL Study
Peter Johnson, MA, MD, FRCP
12th ICML Highlights in Lymphoma published on July 12, 2013

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingMPN.com | PracticalOncologist.com | PracticalHematologist.com | ManagingCVD.com | ManagingSCD.com | MediComWorldwide.com

©2025 MediCom Worldwide, Inc. All rights reserved

  • Privacy, Terms, and Conditions
  • Contact Us